Diseases of the Musculoskeletal System, Phase III

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

Trial with
Ra Pharmaceuticals, Inc.
Ages
40 years - 80 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Richard Nowak

Richard.nowak@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Richard Nowak, MD, MS
Associate Professor of Neurology; Director, Program in Clinical & Translational Neuromuscular Research; Director, Yale Myasthenia Gravis Clinic

Sub-Investigator

Bhaskar Roy, MBBS, MHS

Last Updated
10/08/2024
Study HIC
#2000026786